Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $306.34 million. The enterprise value is $1.27 billion.
Important Dates
The next confirmed earnings date is Tuesday, February 24, 2026, after market close.
| Earnings Date | Feb 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 111.60 million shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | 111.60M |
| Shares Outstanding | 111.60M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | -1.57% |
| Owned by Insiders (%) | 1.65% |
| Owned by Institutions (%) | 89.84% |
| Float | 86.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 12.20 |
| PS Ratio | 0.15 |
| Forward PS | 0.14 |
| PB Ratio | 0.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | 15.90 |
| EV / EBIT | 274.43 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 1.29.
| Current Ratio | 1.33 |
| Quick Ratio | 1.17 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 12.78 |
| Debt / FCF | n/a |
| Interest Coverage | 0.10 |
Financial Efficiency
Return on equity (ROE) is -12.40% and return on invested capital (ROIC) is 0.25%.
| Return on Equity (ROE) | -12.40% |
| Return on Assets (ROA) | 0.12% |
| Return on Invested Capital (ROIC) | 0.25% |
| Return on Capital Employed (ROCE) | 0.23% |
| Weighted Average Cost of Capital (WACC) | 3.80% |
| Revenue Per Employee | $456,456 |
| Profits Per Employee | -$40,197 |
| Employee Count | 4,500 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Evolent Health has paid $430,000 in taxes.
| Income Tax | 430,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.90% in the last 52 weeks. The beta is 0.24, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -72.90% |
| 50-Day Moving Average | 3.66 |
| 200-Day Moving Average | 7.24 |
| Relative Strength Index (RSI) | 26.64 |
| Average Volume (20 Days) | 2,761,978 |
Short Selling Information
The latest short interest is 19.20 million, so 17.21% of the outstanding shares have been sold short.
| Short Interest | 19.20M |
| Short Previous Month | 19.63M |
| Short % of Shares Out | 17.21% |
| Short % of Float | 22.19% |
| Short Ratio (days to cover) | 6.59 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.05 billion and -$180.89 million in losses. Loss per share was -$1.57.
| Revenue | 2.05B |
| Gross Profit | 378.34M |
| Operating Income | 4.63M |
| Pretax Income | -127.75M |
| Net Income | -180.89M |
| EBITDA | 79.84M |
| EBIT | 4.63M |
| Loss Per Share | -$1.57 |
Full Income StatementBalance Sheet
The company has $116.65 million in cash and $1.08 billion in debt, with a net cash position of -$965.67 million or -$8.65 per share.
| Cash & Cash Equivalents | 116.65M |
| Total Debt | 1.08B |
| Net Cash | -965.67M |
| Net Cash Per Share | -$8.65 |
| Equity (Book Value) | 842.23M |
| Book Value Per Share | 7.55 |
| Working Capital | 140.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.19 million and capital expenditures -$79.80 million, giving a free cash flow of -$115.99 million.
| Operating Cash Flow | -36.19M |
| Capital Expenditures | -79.80M |
| Free Cash Flow | -115.99M |
| FCF Per Share | -$1.04 |
Full Cash Flow StatementMargins
Gross margin is 18.42%, with operating and profit margins of 0.23% and -6.24%.
| Gross Margin | 18.42% |
| Operating Margin | 0.23% |
| Pretax Margin | -6.22% |
| Profit Margin | -6.24% |
| EBITDA Margin | 3.89% |
| EBIT Margin | 0.23% |
| FCF Margin | n/a |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.65% |
| Shareholder Yield | -0.65% |
| Earnings Yield | -59.59% |
| FCF Yield | -38.21% |
Analyst Forecast
The average price target for Evolent Health is $10.67, which is 288.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.67 |
| Price Target Difference | 288.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 8.43% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 0.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.91 |
| Piotroski F-Score | 4 |
